Porta Sophia

Porta Sophia is a non-profit organization, founded in the fall of 2020 by David Casimir and Bill Linton, and headquartered in Madison, Wisconsin, USA. Its mission is to protect the public domain, stimulate innovation, and support the issuance of appropriate patents within the field of psychedelics, ultimately aiming to facilitate accessible psychedelic therapies. As a 501(c)(3) entity, all funds generated from its services are reinvested into its operations.

Porta Sophia operates a free online prior art library, which provides curated scientific, historical, and cultural information related to psychedelics. Beyond this public resource, the organization offers specialized prior art services including third-party interventions, patentability assessments, and landscape assessments for stakeholders in the psychedelic patenting process. It also tracks U.S. and international psychedelic patent applications and launched a Chemical Structure Search Tool in March 2025 to aid in analyzing psychedelic derivatives in patents and applications.

Porta Sophia's patent litigation posture is unique; it acts as a proactive patent watchdog rather than a traditional operating company defending suits or an NPE asserting a portfolio. The organization's primary activity involves filing third-party interventions, which are preissuance submissions and observations to patent offices like the USPTO and WIPO. These interventions challenge patent applications deemed overly broad or lacking novelty by presenting relevant prior art to prevent the improper granting of patents. As of mid-September 2023, Porta Sophia had filed 60 such interventions.

One notable case aligns with Porta Sophia's mission: Porta Sophia v. Gregory Ellis, initiated on August 22, 2025, before the Patent Trial and Appeal Board (PTAB). This likely relates to a third-party preissuance submission Porta Sophia filed in June 2024 against Gregory Ellis's patent application for a "Delivery System For Ayahuasca-Like Substances," challenging its patentability with prior art documents. The organization has also been instrumental in challenging claims made by other entities, leading to rejections or amendments in applications from companies such as Pharma America Holding Inc. and COMPASS Pathways.